Worth reading
32Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Items stated in the management plan
Annual updateNet SalesNot disclosed → 12,702 (FY2026 forecast)（+5.9% (compared with FY2025 actual revenue of ¥11,997 million)）
Operating profitNot disclosed → 920 (FY2026 forecast)（+11.4% (compared with FY2025 actual operating income of ¥826 million)）
Net income for the current fiscal yearNot disclosed → 536 (FY2026 forecast)（+10.6% (compared with FY2025 actual net income of ¥485 million)）
Only the target level is shown because the current level for comparison was not provided.What happened to the previous planMost subsidiaries exceeded their plans
Key initiatives
01Developing services that use AI
02Aiming to become “The Streaming AX Company,” driving the use of video
03Efforts to retain and expand business are needed for each customer issue
Plan assumptionsThe global pharmaceutical market is forecast to grow at a CAGR of 6–9% over the five years from 2024 to 2028, compared with 0.5–1.5% growth in Japan (IQVIA, US)., The domestic business-to-business e-learning services market is expected to reach ¥129.3 billion in FY2025 and is forecast to reach ¥133.8 billion in FY2026., The extent of the impact of US tariff measures and other factors is unclear, but they are negative factors
Size of the Target MarketMarket Information delivery services for pharmaceutical companies / Dimensions Approximately ¥96 billion (a potential market three times the current market) / Source SMBC Nikko Securities, Market Japan's pharmaceutical market / Dimensions ¥11 trillion / Source Related to information stated in IQVIA's Global Medicine Spending and Usage Trends report, Market Domestic business-to-business e-learning services market / Dimensions ¥129.3 billion in FY2025 (expected) and ¥133.8 billion in FY2026 (forecast) / Source Yano Research Institute Ltd., “Survey of the E-Learning Market (2026)”
Risks identified by the company
Impact of drug price revisions on promotional budgets
The extent of the impact of US tariff measures and other factors is unclear, but they are negative factors
Commoditization of general video distribution technology
| Item | Details |
|---|---|
| Plan name | Business Plan and Growth Potential |
| Progress against the plan | Annual update |
| Sales Target | Not disclosed → 12,702 (FY2026 forecast)（+5.9% (compared with FY2025 actual revenue of ¥11,997 million)） |
| Operating profit target | Not disclosed → 920 (FY2026 forecast)（+11.4% (compared with FY2025 actual operating income of ¥826 million)） |
| Net income target | Not disclosed → 536 (FY2026 forecast)（+10.6% (compared with FY2025 actual net income of ¥485 million)） |
| Plan assumptions | The global pharmaceutical market is forecast to grow at a CAGR of 6–9% over the five years from 2024 to 2028, compared with 0.5–1.5% growth in Japan (IQVIA, US)., The domestic business-to-business e-learning services market is expected to reach ¥129.3 billion in FY2025 and is forecast to reach ¥133.8 billion in FY2026., The extent of the impact of US tariff measures and other factors is unclear, but they are negative factors |
| Key initiatives | Developing services that use AI, Aiming to become “The Streaming AX Company,” driving the use of video, Efforts to retain and expand business are needed for each customer issue |
| Results under the previous plan | Most subsidiaries exceeded their plans |
| Size of the Target Market | Market Information delivery services for pharmaceutical companies / Dimensions Approximately ¥96 billion (a potential market three times the current market) / Source SMBC Nikko Securities, Market Japan's pharmaceutical market / Dimensions ¥11 trillion / Source Related to information stated in IQVIA's Global Medicine Spending and Usage Trends report, Market Domestic business-to-business e-learning services market / Dimensions ¥129.3 billion in FY2025 (expected) and ¥133.8 billion in FY2026 (forecast) / Source Yano Research Institute Ltd., “Survey of the E-Learning Market (2026)” |
| Risks identified | Impact of drug price revisions on promotional budgets, The extent of the impact of US tariff measures and other factors is unclear, but they are negative factors, Commoditization of general video distribution technology |
| Publication date | June 2026 |
Items this document does not state (14)
Plan periodOperating profit margin targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetNon-financial targetsReason for revision or withdrawalDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.No reason for changing the plan was provided. Regarding FY2025 results, the company explained that although web seminars and content production projects for some major customers in the pharmaceutical market declined, business expanded with new and mid-sized customers, education-related SaaS and technology trading companies. It stated that selling, general and administrative expenses increased due to sales activities, personnel utilization, participation in events and M&A expenses, among other factors, affecting operating income.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.